Danish dermatology company LEO Pharma has announced positive results from the Phase III DELTA 3 trial, an open-label extension study of its candidate delgocitin 30 October 2023
UCB has won two approvals from the US Food and Drug Administration, one for a new first-in-class rare disease med and another, for Bimzelx (bimekizumab-bkzx), b 18 October 2023
Positive results from the Phase III SEQUENCE study show the benefit of AbbVie’s blockbuster biologic Skyrizi (risankizumab) in Crohn's disease. 16 October 2023
Belgian drugmaker UCB has announced the first analyses of pooled data from two Phase III bimekizumab studies (BE HEARD I and BE HEARD II) in moderate to severe 13 October 2023
At the European Academy of Dermatology and Venerology (EADV) congress in Berlin, AbbVie is presenting positive results from the Phase IIb NCT04927975 study. 12 October 2023
Privately-held Swiss dermatology company Galderma has announced some bad news relating to its pending Biologics License Application (BLA) for relabotulinumtoxin 3 October 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.